Moderna Therapeutics establishes new mRNA rare diseases company

12 May 2015

Privately-held Moderna Therapeutics, a specialist in messenger RNA, has launched Elpidera LLC, a new venture focused solely on the advancement of mRNA-based medicines for rare diseases.

Elpidera will leverage Modern’s mRNA platform to create novel therapies in small patient populations with unmet medical needs. Moderna signed a strategic agreement with US drugmaker Alexion Pharmaceuticals (Nasdaq: ALXN) in January 2014 which allowed Alexion to have 10 product options in rare diseases. Elpidera will advance programs proprietary to Moderna, independently of the Alexion programs, while also supporting Alexion’s efforts to leverage the Moderna technology platform through the existing agreement.

Offers hope to thousands

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK